Priothera is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with hematological malignancies through innovative therapies, including the investigational drug mocravimod, which aims to enhance the curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy
Priothera is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with hematological malignancies through innovative therapies, including the investigational drug mocravimod, which aims to enhance the curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy.